The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine‐based therapy. This study aims to explore the real‐world efficacy and safety of 5‐FU/LV‐nal‐IRI. Methods This is a retrospective multicenter analysis including advPDAC patients receiving 5‐FU/LV‐nal‐IRI after failure of gemcitabine‐based therapy. Survival analyses were performed using Kaplan–Meier method, univariate and multivariate analyses by Cox regression. Results A total of 296 patients (median age 64.4 years, ECOG PS ≥1 in 56% of cases) were treated at 11 Italian institutions between 2016 and 2018. 34% of them underwent primary tumor resection, and 79% received gemcitabine‐nabpaclitaxel as first line. 5‐FU/LV‐nal‐IRI was administered as second‐line in 73% of cases. Objective response and disease control rate were 12% and 41%, respectively. Treatment was well tolerated with dose reductions in 50% of patients but no one permanent discontinuation; the commonest grade ≥3 toxicities were neutropenia (14%) and diarrhea (12%). Median PFS and OS from 5‐FU/LV‐nal‐IRI initiation was 3.2 and 7.1 months, respectively. Conclusions These real‐world data confirm the 5‐FU/LV‐nal‐IRI efficacy and safety in advPDAC patients progressed to gemcitabine‐based therapy, with outcomes comparable to NAPOLI‐1, even in a less‐selected population and with more modern therapeutic algorithm..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer Medicine - 12(2023), 13, Seite 14337-14345 |
| Beteiligte Personen: |
Procaccio, Letizia [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Published by John Wiley & Sons Ltd. |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1002/cam4.6111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY01522242X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY01522242X | ||
| 003 | DE-627 | ||
| 005 | 20231111133846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cam4.6111 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CAM4_2023_12_13.zip.xml |
| 035 | |a (DE-627)WLY01522242X | ||
| 035 | |a (WILEY)CAM46111 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Procaccio, Letizia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma |
| 264 | 1 | |c 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Published by John Wiley & Sons Ltd. | ||
| 520 | |a Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine‐based therapy. This study aims to explore the real‐world efficacy and safety of 5‐FU/LV‐nal‐IRI. Methods This is a retrospective multicenter analysis including advPDAC patients receiving 5‐FU/LV‐nal‐IRI after failure of gemcitabine‐based therapy. Survival analyses were performed using Kaplan–Meier method, univariate and multivariate analyses by Cox regression. Results A total of 296 patients (median age 64.4 years, ECOG PS ≥1 in 56% of cases) were treated at 11 Italian institutions between 2016 and 2018. 34% of them underwent primary tumor resection, and 79% received gemcitabine‐nabpaclitaxel as first line. 5‐FU/LV‐nal‐IRI was administered as second‐line in 73% of cases. Objective response and disease control rate were 12% and 41%, respectively. Treatment was well tolerated with dose reductions in 50% of patients but no one permanent discontinuation; the commonest grade ≥3 toxicities were neutropenia (14%) and diarrhea (12%). Median PFS and OS from 5‐FU/LV‐nal‐IRI initiation was 3.2 and 7.1 months, respectively. Conclusions These real‐world data confirm the 5‐FU/LV‐nal‐IRI efficacy and safety in advPDAC patients progressed to gemcitabine‐based therapy, with outcomes comparable to NAPOLI‐1, even in a less‐selected population and with more modern therapeutic algorithm. | ||
| 700 | 1 | |a Merz, Valeria |4 aut | |
| 700 | 1 | |a Fasano, Morena |4 aut | |
| 700 | 1 | |a Vaccaro, Vanja |4 aut | |
| 700 | 1 | |a Giommoni, Elisa |4 aut | |
| 700 | 1 | |a Pretta, Andrea |4 aut | |
| 700 | 1 | |a Noventa, Silvia |4 aut | |
| 700 | 1 | |a Satolli, Maria Antonietta |4 aut | |
| 700 | 1 | |a Giordano, Guido |4 aut | |
| 700 | 1 | |a Zichi, Clizia |4 aut | |
| 700 | 1 | |a Pinto, Carmine |4 aut | |
| 700 | 1 | |a Zecchetto, Camilla |4 aut | |
| 700 | 1 | |a Barsotti, Giulia |4 aut | |
| 700 | 1 | |a De Vita, Ferdinando |4 aut | |
| 700 | 1 | |a Milella, Michele |4 aut | |
| 700 | 1 | |a Antonuzzo, Lorenzo |4 aut | |
| 700 | 1 | |a Scartozzi, Mario |4 aut | |
| 700 | 1 | |a Zaniboni, Alberto |4 aut | |
| 700 | 1 | |a Spadi, Rosella |4 aut | |
| 700 | 1 | |a Casalino, Simona |4 aut | |
| 700 | 1 | |a Bergamo, Francesca |4 aut | |
| 700 | 1 | |a De Toni, Chiara |4 aut | |
| 700 | 1 | |a Melisi, Davide |4 aut | |
| 700 | 1 | |a Lonardi, Sara |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer Medicine |g 12(2023), 13, Seite 14337-14345 |w (DE-627)WLY003024768 |x 20457634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:13 |g pages:14337-14345 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 13 |h 14337-14345 |g 9 | ||